FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185877454> ?p ?o ?g. }

• W2185877454 abstract "METHODS We conducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between 3 and 60 years of age from Asia (81.3%) or Africa (18.7%) with microscopically confirmed, uncomplicated P. falciparum malaria. Patients underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mef lo quine plus 100 mg of artesunate. Doses were calculated according to body weight and administered once daily for 3 days. RESULTS Pyronaridine–artesunate was noninferior to mef lo quine plus artesunate for the primary outcome: adequate clinical and parasitologic response in the per-protocol population on day 28, corrected for reinfection with the use of polymerase-chain-reaction (PCR) genotyping. For this outcome, efficacy in the group receiving pyronaridine– artesunate was 99.2% (743 of 749 patients; 95% confidence interval [CI], 98.3 to 99.7) and that in the group receiving mef lo quine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8 to 99.1), with a treatment difference of 1.4 percentage points (95% CI, 0.0 to 3.5; P = 0.05). In the intention-to-treat population, efficacy on day 42 in the group receiving pyronaridine–artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4 to 85.6) and that in the group receiving mef lo quine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1 to 87.3). In Cambodia, where there were 211 study patients, the median parasite clearance time was prolonged for both treatments: 64 hours versus 16.0 to 38.9 hours in other countries (P<0.001, on the basis of Kaplan–Meier estimates). Kaplan–Meier estimates of the recrudescence rate in the intention-to-treat population in Cambodia until day 42 were higher with pyronaridine–artesunate than with mef loquine plus artesunate (10.2% [95% CI, 5.4 to 18.6] vs. 0%; P = 0.04 as calculated with the log-rank test), but similar for the other countries combined (4.7% [95% CI, 3.3 to 6.7] and 2.8% [95% CI, 1.5 to 5.3], respectively; P = 0.24). Elevated levels of aminotransferases were observed in those receiving pyronaridine–artesunate. Two patients re ceiving mef lo quine plus artesunate had seizures. CONCLUSIONS Fixed-dose pyronaridine–artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria. In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin. (Funded by Shin Poong Pharmaceutical Company and the Medicines for Malaria Venture; ClinicalTrials.gov number, NCT00403260.)" @default.
• W2185877454 created "2016-06-24" @default.
• W2185877454 creator A5002286185 @default.
• W2185877454 creator A5012856970 @default.
• W2185877454 creator A5019211222 @default.
• W2185877454 creator A5020426141 @default.
• W2185877454 creator A5023145210 @default.
• W2185877454 creator A5023712262 @default.
• W2185877454 creator A5026917090 @default.
• W2185877454 creator A5033676700 @default.
• W2185877454 creator A5034311856 @default.
• W2185877454 creator A5043866303 @default.
• W2185877454 creator A5047055692 @default.
• W2185877454 creator A5051155517 @default.
• W2185877454 creator A5068237755 @default.
• W2185877454 creator A5080121371 @default.
• W2185877454 creator A5082795829 @default.
• W2185877454 creator A5091606603 @default.
• W2185877454 date "2012-01-01" @default.
• W2185877454 modified "2023-09-26" @default.
• W2185877454 title "Pyronaridine-Artesunate versus Mef lo quine plus Artesunate for Malaria" @default.
• W2185877454 cites W1576298050 @default.
• W2185877454 cites W1825014948 @default.
• W2185877454 cites W1951642591 @default.
• W2185877454 cites W1990296740 @default.
• W2185877454 cites W1990484619 @default.
• W2185877454 cites W1993147489 @default.
• W2185877454 cites W2040713555 @default.
• W2185877454 cites W2070076574 @default.
• W2185877454 cites W2076655844 @default.
• W2185877454 cites W2100876932 @default.
• W2185877454 cites W2109280888 @default.
• W2185877454 cites W2111539591 @default.
• W2185877454 cites W2118778815 @default.
• W2185877454 cites W2122967261 @default.
• W2185877454 cites W2125397010 @default.
• W2185877454 cites W2126591359 @default.
• W2185877454 cites W2135011211 @default.
• W2185877454 cites W2146162023 @default.
• W2185877454 cites W2157912408 @default.
• W2185877454 cites W2161311583 @default.
• W2185877454 cites W2161510631 @default.
• W2185877454 cites W2233190715 @default.
• W2185877454 cites W2408646562 @default.
• W2185877454 cites W2412769573 @default.
• W2185877454 hasPublicationYear "2012" @default.
• W2185877454 type Work @default.
• W2185877454 sameAs 2185877454 @default.
• W2185877454 citedByCount "0" @default.
• W2185877454 crossrefType "journal-article" @default.
• W2185877454 hasAuthorship W2185877454A5002286185 @default.
• W2185877454 hasAuthorship W2185877454A5012856970 @default.
• W2185877454 hasAuthorship W2185877454A5019211222 @default.
• W2185877454 hasAuthorship W2185877454A5020426141 @default.
• W2185877454 hasAuthorship W2185877454A5023145210 @default.
• W2185877454 hasAuthorship W2185877454A5023712262 @default.
• W2185877454 hasAuthorship W2185877454A5026917090 @default.
• W2185877454 hasAuthorship W2185877454A5033676700 @default.
• W2185877454 hasAuthorship W2185877454A5034311856 @default.
• W2185877454 hasAuthorship W2185877454A5043866303 @default.
• W2185877454 hasAuthorship W2185877454A5047055692 @default.
• W2185877454 hasAuthorship W2185877454A5051155517 @default.
• W2185877454 hasAuthorship W2185877454A5068237755 @default.
• W2185877454 hasAuthorship W2185877454A5080121371 @default.
• W2185877454 hasAuthorship W2185877454A5082795829 @default.
• W2185877454 hasAuthorship W2185877454A5091606603 @default.
• W2185877454 hasConcept C126322002 @default.
• W2185877454 hasConcept C168563851 @default.
• W2185877454 hasConcept C203014093 @default.
• W2185877454 hasConcept C204243189 @default.
• W2185877454 hasConcept C2778048844 @default.
• W2185877454 hasConcept C2778059366 @default.
• W2185877454 hasConcept C2778371730 @default.
• W2185877454 hasConcept C2908647359 @default.
• W2185877454 hasConcept C44249647 @default.
• W2185877454 hasConcept C71924100 @default.
• W2185877454 hasConcept C90924648 @default.
• W2185877454 hasConcept C98274493 @default.
• W2185877454 hasConcept C99454951 @default.
• W2185877454 hasConceptScore W2185877454C126322002 @default.
• W2185877454 hasConceptScore W2185877454C168563851 @default.
• W2185877454 hasConceptScore W2185877454C203014093 @default.
• W2185877454 hasConceptScore W2185877454C204243189 @default.
• W2185877454 hasConceptScore W2185877454C2778048844 @default.
• W2185877454 hasConceptScore W2185877454C2778059366 @default.
• W2185877454 hasConceptScore W2185877454C2778371730 @default.
• W2185877454 hasConceptScore W2185877454C2908647359 @default.
• W2185877454 hasConceptScore W2185877454C44249647 @default.
• W2185877454 hasConceptScore W2185877454C71924100 @default.
• W2185877454 hasConceptScore W2185877454C90924648 @default.
• W2185877454 hasConceptScore W2185877454C98274493 @default.
• W2185877454 hasConceptScore W2185877454C99454951 @default.
• W2185877454 hasLocation W21858774541 @default.
• W2185877454 hasOpenAccess W2185877454 @default.
• W2185877454 hasPrimaryLocation W21858774541 @default.
• W2185877454 hasRelatedWork W101114207 @default.
• W2185877454 hasRelatedWork W2062379374 @default.
• W2185877454 hasRelatedWork W2074080264 @default.
• W2185877454 hasRelatedWork W2112962985 @default.
• W2185877454 hasRelatedWork W2130637578 @default.

• next